InVivo Therapeutics (NSDQ:NVIV) said today it added its 1st UK-based site to the Inspire study of its neuro-spinal scaffold at Middlesbrough’s James Cook University Hospital, bringing the total number of sites up to 33.
The Cambridge, Mass.-based company’s neuro-spinal scaffold is designed to be surgically implanted following acute spinal cord injuries to act as a physical substrate for nerve sprouting.
InVivo said Dr. Manjunath Prasad will join the study at the site, within the Golden Jubilee Regional Spinal Cord Injuries Centre at the hospital.
“I am enthusiastic about the opportunity to be joining the Inspire study and I look forward to helping InVivo evaluate this exciting experimental technology while bringing awareness of the study to the United Kingdom,” Dr. Prasad said in a prepared statement.
“We are thrilled to open our 1st Inspire site in the United Kingdom and are looking forward to working with Dr. Prasad and the staff at James Cook University Hospital. The Inspire Study is now open for enrollment across 3 countries: the United States, Canada, and the United Kingdom,” CEO & chair Mark Perrin said in a press release.
Late last month, InVivo said that 2 patients in the Inspire trial of its neuro-spinal scaffold have shown significant improvements in motor recovery assessments.
